Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery

Not Applicable

Completed

• Conditions: Cardiac Surgery
• Interventions: Drug: rhEPO

• Registration Number: NCT00939978
• Lead Sponsor: Yonsei University

Brief Summary

The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2009-07-14
• Study First Submitted QC: 2009-07-14
• Study First Posted: 2009-07-15
• Primary Completion: 2010-06
• Study Completion: 2010-07
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-06
• Last Update Posted: 2010-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• The 90 patients who are planned to have the heart surgery during this study period.(minimum age 20)

Exclusion Criteria

• Uncontrolled hypertension(diastolic blood pressure(DBP)>100 mmHg), Hct > 45%, Plt. count)>450,000
• There are no history of seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis.
• No pregnancy, acute hyper parathyroidism.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
saline	rhEPO	-
Venoferrum	rhEPO	-

Trial Locations

Locations (1)

Severance hospital; 🇰🇷 Seoul, Korea, Republic of